Search Results - "Shitara, K."

New agents on the horizon in gastric cancer by Lordick, F., Shitara, K., Janjigian, Y.Y.

“…Conventional cytotoxic chemotherapy has been the backbone of advanced gastric cancer treatment for decades and still represents a key element of the…”
Get full text

Response to the letter to the Editor: TMB cut-offs fail to predict benefit of PD-1 blockade in gastroesophageal adenocarcinoma in KEYNOTE-061 by Shitara, K., Lunceford, J.

Get full text

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer by Yokota, T, Ura, T, Shibata, N, Takahari, D, Shitara, K, Nomura, M, Kondo, C, Mizota, A, Utsunomiya, S, Muro, K, Yatabe, Y

“…Background: Activating mutation of KRAS and BRAF are focused on as potential prognostic and predictive biomarkers in patients with colorectal cancer (CRC)…”
Get full text

Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial by Yamazaki, K., Yamanaka, T., Shiozawa, M., Manaka, D., Kotaka, M., Gamoh, M., Shiomi, A., Makiyama, A., Munemoto, Y., Rikiyama, T., Fukunaga, M., Ueki, T., Shitara, K., Shinkai, H., Tanida, N., Oki, E., Sunami, E., Ohtsu, A., Maehara, Y., Yoshino, T.

“…Oxaliplatin-based adjuvant chemotherapy may be associated with debilitating peripheral sensory neuropathy (PSN) in patients with high-risk stage II colon…”
Get full text

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS by Muro, K., Van Cutsem, E., Narita, Y., Pentheroudakis, G., Baba, E., Li, J., Ryu, M -H, Zamaniah, W I Wan, Yong, W -P, Yeh, K -H, Kato, K., Lu, Z., Cho, B.C., Nor, I.M., Ng, M., Chen, L -T, Nakajima, T.E., Shitara, K., Kawakami, H., Tsushima, T., Yoshino, T., Lordick, F., Martinelli, E., Smyth, E.C., Arnold, D., Minami, H., Tabernero, J., Douillard, J -Y

“…The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of gastric…”
Get full text

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS by Muro, K., Lordick, F., Tsushima, T., Pentheroudakis, G., Baba, E., Lu, Z., Cho, B.C., Nor, I.M., Ng, M., Chen, L -T, Kato, K., Li, J., Ryu, M -H, Zamaniah, W I Wan, Yong, W -P, Yeh, K -H, Nakajima, T.E., Shitara, K., Kawakami, H., Narita, Y., Yoshino, T., Van Cutsem, E., Martinelli, E., Smyth, E.C., Arnold, D., Minami, H., Tabernero, J., Douillard, J -Y

“…The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of…”
Get full text

Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma by Shitara, K., Özgüroğlu, M., Bang, Y.-J., Di Bartolomeo, M., Mandalà, M., Ryu, M.-H., Caglevic, C., Chung, H.C., Muro, K., Van Cutsem, E., Kobie, J., Cristescu, R., Aurora-Garg, D., Lu, J., Shih, C.-S., Adelberg, D., Cao, Z.A., Fuchs, C.S.

“…In the phase III KEYNOTE-061 trial (NCT02370498), pembrolizumab did not significantly improve overall survival versus paclitaxel as second-line therapy for…”
Get full text

REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients by Shitara, K., Yamanaka, T., Denda, T., Tsuji, Y., Shinozaki, K., Komatsu, Y., Kobayashi, Y., Furuse, J., Okuda, H., Asayama, M., Akiyoshi, K., Kagawa, Y., Kato, T., Oki, E., Ando, T., Hagiwara, Y., Ohashi, Y., Yoshino, T.

“…The objective of this randomized phase II trial was to evaluate efficacy and safety of the therapeutic sequence of regorafenib followed by cetuximab, compared…”
Get full text

Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer by Kubota, Y., Kawazoe, A., Mishima, S., Nakamura, Y., Kotani, D., Kuboki, Y., Bando, H., Kojima, T., Doi, T., Yoshino, T., Kuwata, T., Shitara, K.

“…We conducted comprehensive clinical and molecular characterization of claudin 18.2 expression (CLDN18.2) in advanced gastric or gastroesophageal junction…”
Get full text

Timing of Initiation of Adjuvant Chemotherapy for Gastric Cancer: A Case-Matched Comparison Study of Laparoscopic vs. Open Surgery by Kaito, Akio, MD, Kinoshita, Takahiro, MD, PhD, FACS, Shitara, Kouhei, MD, PhD, Shibasaki, Hidehito, MD, PhD, Nishida, Toshirou, MD, PhD, FACS

“…Abstract Background Laparoscopic gastrectomy (LG) is reported to be associated with faster recovery than open gastrectomy (OG); however, the influence of the…”
Get full text

195TiP GLOW: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2⁺/HER2⁻ advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ) by Xu, R-H., Ajani, J.A., Al-Batran, S-E., Bang, Y-J., Catenacci, D., Enzinger, P.C., Ilson, D.H., Kim, S., Lordick, F., Shitara, K., van Cutsem, E., Arozullah, A., Park, J.W., Shah, M.A.

Get full text

583P Effect of infusion rate, premedication, and prophylactic peg-filgrastim treatment on the safety of the liposomal formulation of eribulin (E7389-LF): Results from the expansion part of a phase I study by Iwasa, S., Takahashi, S., Hirao, M., Kato, K., Shitara, K., Sato, Y., Hamakawa, T., Horinouchi, H., Tahara, M., Chin, K., Mizutani, M., Suzuki, T., Takase, T., Matsunaga, R., Mukohara, T.

Get full text

Role of Nivolumab in the Management of First-Line Unresectable Advanced or Recurrent Gastric Cancer in Combination with Chemotherapy: Lessons from the Japanese Experience by Kubota, Yohei, Aoki, Yu, Kawazoe, Akihito, Shitara, Kohei

“…Recently, immune checkpoint inhibitor (ICI), such as anti-programmed cell death-1 (PD-1) or programmed cell death ligand-1 (PD-L1) monoclonal antibodies, has…”
Get full text

Safety and efficacy of trifluridine/tipiracil (TAS-102) plus bevacizumab in clinical practice for patients with refractory metastatic colorectal cancer by Kotani, D., Kuboki, Y., Yasuda, K., Nakamura, Y., Kawazoe, A., Bando, H., Taniguchi, H., Shitara, K., Yoshino, T.

Get full text

A randomized, phase II, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer by Shitara, K., Bang, Y.-J., Sakai, D., Yasui, H., Kawaguchi, Y., Sugihara, M., Saito, K., Dalal, R., Yamaguchi, K.

Get full text

Relation of overall survival, progression free survival, post progression survival and response rate in four randomized Japanese phase III trials comparing various combinations of S-1 therapy for first-line treatment of advanced gastric cancer by Takeuchi, M., Ichikawa, W., Shitara, K., Sunakawa, Y., Oba, K., Koizumi, W., Sakata, Y., Furukawa, H., Takeuchi, M., Fujii, M.

Get full text

LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study by Moehler, M., Shitara, K., Garrido, M., Salman, P., Shen, L., Wyrwicz, L., Yamaguchi, K., Skoczylas, T., Campos Bragagnoli, A., Liu, T., Schenker, M., Yanez, P., Tehfe, M., Poulart, V., Cullen, D., Lei, M., Kondo, K., Li, M., Ajani, J.A., Janjigian, Y.Y.

Get full text

The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced pancreatic cancer by Izawa, N., Morizane, C., Takahashi, H., Ueno, M., Kawamoto, Y., Okano, N., Shimizu, S., Sudo, K., Itoh, S., Asagi, A., Kagawa, Y., Kamata, K., Kudo, T., Nomura, S., Kuwata, T., Fujii, S., Okamoto, W., Shitara, K., Ohtsu, A., Yoshino, T.

Get full text

The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced esophageal cancer by Kato, K., Kojima, T., Saeki, H., Hara, H., Kajiwara, T., Hironaka, S., Nakatsumi, H., Kadowaki, S., Kagawa, Y., Esaki, T., Moriwaki, T., Kobayashi, T., Izawa, N., Nomura, S., Kuwata, T., Fujii, S., Okamoto, W., Shitara, K., Ohtsu, A., Yoshino, T.

Get full text

KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer: a double-blind, randomized, placebo-controlled phase 3 study by Chung, H., Bang, Y., Fuchs, C., Qin, S., Satoh, T., Shitara, K., Tabernero, J., Van Cutsem, E., Cao, Z., Chen, X., Kang, S., Shih, C., Janjigian, Y.

Get full text